GEVORKYAN v H1 2026: tržby +18 %, čistý zisk +34 %

GEVORKYAN reported H1 2026 revenue of €49.8 million, up 18.18% year over year, while net profit rose 34.50% to €3.97 million. EBITDA increased 9.19% to €15.04 million and the EBITDA margin reached 30.19%; EBIT grew 29.06% to €6.68 million. The completed Italian acquisition and EN 9100 aerospace/defense certification have generated new aircraft and unmanned-systems projects, with its Italian unit already supplying Rheinmetall's group.

Analysis

The earnings mix implies a favorable quality shift rather than a pure volume story: operating profit and net income are growing materially faster than EBITDA despite modest EBITDA-margin compression. That points to improved depreciation/interest/tax absorption or mix, but the distinction matters—without audited cash flow, investors should not capitalize the higher net-income growth as recurring until working capital, acquisition accounting, and maintenance capex are disclosed. For a small-cap supplier, the near-term valuation response is likely constrained more by liquidity and reporting credibility than by the headline growth rate.

The aerospace/defense qualification creates a potentially valuable barrier to entry, but certification is an option on future program wins, not evidence of booked revenue. The Italian acquisition's supply relationship with Rheinmetall (RHM) could increase GEV's customer concentration and expose it to procurement-cycle timing, while RHM's direct financial sensitivity is immaterial. More broadly, powder-metallurgy capacity may benefit from European defense localization, but margin upside will depend on whether GEV can pass through alloy powder, energy, and labor costs under multi-year contracts.

Immediate upside in GEV is plausible if the market had discounted weak integration execution, but the 1-3 month catalyst is the full interim report: order backlog, aerospace/defense revenue share, net debt, operating cash conversion, and Sinteris purchase-price allocation are the gating data. Over 6-18 months, repeat aerospace qualifications and production-program awards could justify multiple expansion; conversely, a revenue slowdown or EBITDA margin below 30% would reveal that growth is being purchased through lower-margin acquisition volume. Consensus may overstate the RHM read-through: this is strategically validating for GEV but too small to alter RHM earnings expectations.

Key Decisions for Investors

• GEV: place on an accumulation watchlist rather than initiate on the release. Buy only after the full report confirms positive operating cash flow, stable/improving net leverage, and disclosed backlog growth; target a 6-12 month position sized for small-cap liquidity risk, with thesis invalidated by sub-30% EBITDA margin or adverse integration charges.
• GEV: use a staged entry around the next audited/full financial disclosure—one-third on verified cash conversion, two-thirds upon evidence that aerospace/defense orders are serial-production rather than qualification-stage. Avoid extrapolating the current net-income growth rate until acquisition accounting and financing costs are reconciled.
• RHM: no standalone trade from this supplier development. Maintain RHM exposure only on its own defense-order and margin catalysts; treat any GEV supply-chain announcement as a qualitative European sourcing signal, not a measurable earnings driver.
• Monitor European defense procurement awards and EN 9100/OASIS-linked customer wins over the next 6-18 months. A named multiyear production award with revenue, duration, and pricing disclosure would upgrade GEV from an execution watch to a growth position; absent those details, assume certification value is not yet monetized.